Select Page

The QClamp® KRAS Mutation Detection Test for plasma and Formalin-Fixed Paraffin-Embedded (FFPE) samples aids in the identification of cancer patients eligible for treatment and in monitoring response to therapy, which can lead to improved outcomes in cancer patients. The QClamp® KRAS Mutation Detection Test is an in vitro diagnostic real-time quantitative PCR assay for the detection of somatic mutations in and near codons 12 and 13 in Exon 2, codons 59 and 61 in Exon 3, and codons 117 and 146 in Exon 4 in the human KRAS gene, using purified DNA extracted from FFPE or plasma.

Powered by XNA technology, the QClamp® KRAS Mutation Detection Test has achieved a much higher analytical sensitivity compared to other commercial qPCR kits and other cancer gene mutation detection methods. QClamp® KRAS Mutation Detection Test is able to reliably detect 0.1% to 0.5% mutant DNA out of wild-type DNA for targeted mutations, providing lower detection limit compared to similar assays available in the market due to robust enrichment of mutant sequences while suppressing amplification of wild-type sequences.

Learn More about QClamp® Assays >

Product Catalog

QClamp® KRAS Mutation Detection Test – CE Version: DC-10-3010

QClamp® KRAS Mutation Detection Test – Research-Use Version: DC-10-3010R

Pack Size: 30 Samples

Customized Kits Offering

Pick one or more existing NRAS target from the standard KRAS kit: Codons 12, 13, 59, 61, 117 and 146

Service Offering

We provide research service for QClamp® KRAS Mutation Detection Test.


Advantages of QClamp® KRAS Mutation Detection Test


Reliably detects 0.1% to 0.5% VAF mutant DNA out of wild-type DNA for targeted mutations


Suitable for
plasma and FFPE samples  


Minimum 5ng input DNA per reaction. Less than 2 tubes of blood (10mL each) needed for cfDNA


Covering all relevant somatic mutations in 6 codons of KRAS oncogene


Less than 4 hours of
assay run time  


Validated on the most common
qPCR machines with minimized variability

KRAS Mutation and Cancer

The Most Frequently Mutated Oncogene in Cancer

One of the common cancer gene mutations, Kirsten rat sarcoma viral oncogene (KRAS) mutations, are found in several cancers including pancreatic (80 to 90%), colorectal (25 to 60%), lung (25 to 60%) cancers, and are associated with poor prognosis. Mutations in KRAS may lead to abnormal growth signaling by the p21-ras protein, resulting in alterations in cell growth and division and triggering cancer development. Currently, there is no effective treatment for cancers carrying KRAS mutations and KRAS protein is not directly druggable.

KRAS as an Important Biomarker for Targeted Therapy

KRAS is an effector molecule involved in the transduction of signals from the epidermal growth factor receptor (EGFR) to the nucleus. EGFR is overexpressed in metastatic colorectal cancer (mCRC) and is an effective therapeutic target. Discovery of activating mutations in KRAS (exon 2, codons 12 and 13) that affect the efficiency of EGFR treatment has led to the use of KRAS biomarkers to predict patient response to drug therapy. For example, a KRAS mutation is considered to be a strong prognostic marker of response to tyrosine kinase inhibitors such as gefitinib (Iressa) or erlotinib (Tarceva). KRAS mutations have also been detected in many colorectal cancer patients and are associated with responses to cetuximab (Erbitux) or panitumumab (Vectibix), which are used in colon cancer therapy.

Recent Clinical Study

A recent clinical study found that about fifty percent of patients harboring wild-type KRAS and became drug-resistant during the course of treatment had gained new KRAS mutations. The PEAK Phase 2 clinical study of Panitumumab and Bevacizumab plus mFOLFOX6 for first-line treatment of mCRC illustrated the need to extend testing of KRAS mutations at codons 61, 117 and 146 for selection of patients who would respond to anti-KRAS antibody combination therapy.

Supporting Data for QClamp® KRAS Mutation Detection Test

QClamp® KRAS Mutation Detection Test analytical sensitivity in plasma: Detects as low as 0.5% VAF mutant DNA in a 5ng input

cfDNA extracted from plasma of a colorectal cancer patient with known KRAS G12D mutation was diluted in 5ng/μl of wild-type cfDNA. VAF of the sample was verified by Next-Generation Sequencing (NGS). The KRAS c12 assay was able to detect as low as 7-8 KRAS G12D mutant gene copies (0.5% VAF) in the background of wild-type cfDNA.

QClamp® KRAS Mutation Detection Test analytical sensitivity in FFPE: detects as low as 0.1% VAF mutant DNA in a 5ng input

DNA extracted from FFPE of a colorectal cancer patient with known KRAS G12D mutation was diluted in 5ng/μl of wild-type FFPE DNA. VAF of the sample was verified by NGS. The KRAS c12 assay was able to detect as low as 1.5 KRAS G12D mutant gene copies (0.1% VAF) in the background of wild-type FFPE DNA.

Streamlined Workflow for QClamp® Gene Mutation Detection Tests

Step 1: DNA Isolation & Quantification

Extract DNA from FFPE or plasma using a commercial DNA extraction kit and measure the concentration using fluorometric analysis


Step 2: set up qpcr

Mix the assay reagents, load into PCR plate, add controls and extracted DNA ~ 30-60 minutes

Step 3: Amplification parameters

Enter amplification parameters on
qPCR instrument, load PCR plate
and start the run ~ 2.5 hours

Step 4: Data analysis

Determine the presence or absence
of mutations according to the Cq
value cutoffs ~ 15 minutes


Catalog Number 

CE Catalog Number: DC-10-3010;
Research-use-only (RUO) catalog number: DC-10-3010R

Pack Size

30 samples

Detected Codons

Codons 12, 13, 59, 61, 117 and 146

Sample Type

Plasma and FFPE

Input DNA


Validated Instruments

Roche LightCycler® 480, Bio-Rad CFX384 and ABI QuantStudio 5

Detection Channel


Detection Chemistry


Turnaround Time

Less than 4 hours


Stable for 12 months at -25 ℃ to -15 ℃

Most frequent KRAS mutations detected by QClamp® KRAS Mutation Detection Test

ExonAmino Acid Change Nucleotide change Cosmic No.
Q61>Hc.183A>C & c.183A>T554/555
K117>Nc.351A>C & c.351A>T19940/28519


Ordering Information

For products that are in stock, DiaCarta will arrange shipment in 1-3 days. For products that are on backorder, DiaCarta will arrange shipment in 3-5 weeks.
Intended Use: QClamp® KRAS Mutation Detection Test is CE/IVD-certified. Outside USA, this product is available for diagnostic use (CE/IVD) and research use (RUO). In the USA, this product is provided for research use only (RUO) and not for diagnostic use. DiaCarta ships CE/IVD version to locations outside USA and ships RUO version within the USA. Please call 1-800-246-8878 or email if you have questions or specific needs.
Shipping Condition: QClamp® KRAS Mutation Detection Test will be shipped with dry ice. For domestic shipment, DiaCarta provides overnight delivery through FedEx Domestic Overnight Shipping Service. For international shipment, DiaCarta provides 3-7 days in transit through FedEx International Priority Shipping Service. Please contact DiaCarta if you prefer to use your own shipping carrier.

Need Help?

Call us: +1 (800) 246-8878

Email us:

Contact Us!

Ready to Subscribe and Learn?

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!